Fiocruz and DNDi sign a strategic alliance

13 March 2023

Fiocruz, Brazil’s scientific institution for R&D, and the Drugs for Neglected Diseases Initiative (DNDi) have signed a strategic alliance agreement, which expands and strengthens the relationship between the two institutions.

The alliance's goal is to implement, by 2027, actions that help ensuring drugs are developed and delivered to patients in often neglected communities, in an agreement that should not be limited to Latin America.

Under the accord, the alliance will seek to promote the development of drugs and biopharmaceuticals for viral diseases and neglected tropical diseases; improve the access of neglected populations to drugs; promote clinical trials; foster open science and data sharing; in addition to educational initiatives on neglected diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK